Latest Medical Imaging News

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Micro-X has reached a key development milestone with the completion of its first Full Body CT laboratory test bench, securing a $1.6 million payment from US government partner ARPA-H and advancing its innovative medical imaging program.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.

Mach7 Technologies has completed its on-market share buy-back, acquiring over six million shares at an average price well below the initial $5 million cap. The move signals a cautious but confident approach to capital management amid evolving market conditions.

IMEXHS Limited delivered FY25 results at the top end of guidance, reporting a 10% revenue increase and a tripling of underlying EBITDA. The company’s software and radiology services both showed solid growth, setting the stage for an optimistic FY26 outlook.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Lodestar Minerals has reported high-grade heavy rare earth element assays up to 3.73% TREO from its Virgin Mountain project in Arizona, significantly surpassing previous results and highlighting its strategic potential in the US critical minerals landscape.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.

Micro-X has initiated installation of its first human pilot site for a portable Head CT scanner at Royal Melbourne Hospital, marking a pivotal step towards revolutionising stroke diagnosis with carbon nanotube technology.